Abrocitinib for atopic dermatitis after biologic therapy
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema for at least 1 year.
- You are 12 years or older.
- Your eczema is moderate to severe and diagnosed by a skin specialist.
- You have tried 1 or 2 biologic therapies (like shots or infusions) and they either didn't work well or caused side effects.
- You are willing to take abrocitinib as prescribed and come to clinic visits as usual.
- You have not used abrocitinib or any similar JAK inhibitor pill before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study tests if the pill abrocitinib can help people with Down syndrome who have atopic dermatitis (eczema) or alopecia areata (patchy hair loss). The goal is to see if it improves their skin or hair with manageable side effects.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
This study looks at how well two types of advanced medications, dupilumab and JAK inhibitors, work for people with moderate-to-severe atopic dermatitis. It helps doctors learn which treatments are most effective in real-world settings.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.